Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$13.89
-1.4%
$14.32
$10.57
$33.33
$2.02B1.321.12 million shs1.53 million shs
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
$7.05
-0.6%
$6.77
$4.70
$10.44
$532.65M2.521.35 million shs1.27 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$34.64
-3.5%
$33.73
$27.12
$60.90
$2.08B2.38970,850 shs1.49 million shs
Vericel Corporation stock logo
VCEL
Vericel
$42.02
+0.6%
$41.44
$37.39
$63.00
$2.12B1.33411,353 shs610,187 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-1.42%-4.54%+1.46%-3.74%-32.64%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-0.56%-1.67%+1.59%+4.91%-3.69%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-3.48%+3.34%+21.67%-19.24%-31.49%
Vericel Corporation stock logo
VCEL
Vericel
+0.57%-1.52%+2.31%-9.17%-3.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.3831 of 5 stars
4.51.00.04.72.62.50.0
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
1.4208 of 5 stars
3.60.00.00.01.40.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1208 of 5 stars
4.41.00.04.42.20.80.6
Vericel Corporation stock logo
VCEL
Vericel
2.3025 of 5 stars
3.51.00.00.01.40.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71142.72% Upside
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
3.27
Buy$25.50261.70% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4045.50% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1445.51% Upside

Current Analyst Ratings Breakdown

Latest MNMD, DNLI, TWST, and VCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/13/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $32.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.11N/AN/A$8.53 per share1.63
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/A$3.21 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.63N/AN/A$8.07 per share4.29
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.92$0.31 per share134.47$5.92 per share7.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,401.1395.50N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest MNMD, DNLI, TWST, and VCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$0.36-$0.35+$0.01-$0.35N/AN/A
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.56
9.56
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
0.10
7.27
7.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
27.91%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12.50%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.45%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million127.12 millionOptionable
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
4075.55 million73.70 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million47.73 millionOptionable

Recent News About These Companies

Stephens Reaffirms Overweight Rating for Vericel (NASDAQ:VCEL)
Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$13.89 -0.20 (-1.42%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$13.99 +0.10 (+0.69%)
As of 06/20/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mind Medicine (MindMed) stock logo

Mind Medicine (MindMed) NASDAQ:MNMD

$7.05 -0.04 (-0.56%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$7.04 -0.01 (-0.14%)
As of 06/20/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$34.64 -1.25 (-3.48%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$35.43 +0.79 (+2.28%)
As of 06/20/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$42.02 +0.24 (+0.57%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$42.05 +0.03 (+0.07%)
As of 06/20/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.